| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.003 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |